Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 2 clients • 11 examiners • 7 art units • 0 of 11 (0%) have an AI response strategy ready
Cepeda Patent Law, LLC. operates in the Biotechnology & Pharmaceuticals technology area with 33 career applications. The firm currently has 7 pending office actions. Its resolved allowance rate is 33.33 percent.
The firm averages 6.0 office actions per allowance. This metric indicates the number of responses typically required for applications that reach a grant. For practitioners, the 33.33 percent allowance rate and the 6.0 average office actions per allowance provide a benchmark for the expected success and the procedural challenges involved in prosecuting life sciences patents through this firm.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 4 (36%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
| DRISCOLL, MAUREEN VARINA | 1 | 63.7% | +40.8% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| GURLEY, JAMI MICHELLE | 1 | 53.3% | +16.1% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | BAZARGANI, ARYA AHMADI | — |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
| 18687882 | METHOD TO OBTAIN A PURIFIED ANTIBODY COMPOSITION | MEAH, MOHAMMAD Y | — |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DRISCOLL, MAUREEN VARINA | — |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | LANDSMAN, ROBERT S | — |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | VAN DRUFF, SYDNEY | — |
| 18273142 | FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF | TAYLOR, LIA ELAN | — |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | GURLEY, JAMI MICHELLE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Dr. Reddy's | 8 |
| KASHIV BIOSCIENCES, LLC | 3 |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1624 | 1 |
| 1641 | 1 |
| 1647 | 1 |
| 1654 | 1 |
| 1628 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19049310 | LIQUID INJECTABLE COMPOSITIONS OF LURBINECTEDIN | DR. REDDY'S LABORATORIES LIMITED | BAZARGANI, ARYA AHMADI | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2025 |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | Kashiv Biosciences, LLC | WILLIS, DOUGLAS M | 1624 | §112DP | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18687882 | METHOD TO OBTAIN A PURIFIED ANTIBODY COMPOSITION | DR. REDDY'S LABORATORIES LIMITED | MEAH, MOHAMMAD Y | §103 | Non-Final OA | — | Pending | Feb 29, 2024 | |
| 18685082 | A PROCESS TO PRODUCE A PHARMACEUTICAL COMPOSITION | DR. REDDY'S LABORATORIES LIMITED | DRISCOLL, MAUREEN VARINA | §103§112 | Non-Final OA | — | Pending | Feb 20, 2024 | |
| 18681162 | Method To Purify An Antibody Composition Using Cation Exchange Chromatography | DR. REDDY'S LABORATORIES LIMITED | LANDSMAN, ROBERT S | §102§112DP | Non-Final OA | — | Pending | Feb 05, 2024 | |
| 18291909 | Method To Control High Molecular Weight Aggregates In An Antibody Composition | DR. REDDY'S LABORATORIES LIMITED | VAN DRUFF, SYDNEY | §102§103 | Non-Final OA | — | Pending | Jan 24, 2024 | |
| 18273142 | FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF | DR. REDDY'S LABORATORIES LIMITED | TAYLOR, LIA ELAN | 1641 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18038282 | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME | DR. REDDY'S LABORATORIES LIMITED | GURLEY, JAMI MICHELLE | 1647 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | Kashiv Biosciences, LLC | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17779015 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC | CORNET, JEAN P | 1628 | §103§112DPOther | Non-Final OA | — | Pending | May 23, 2022 |
| 17766823 | STABLE FORMULATION OF INTEGRIN ANTIBODY | DR. REDDY'S LABORATORIES LIMITED | MCCOLLUM, ANDREA K | 1674 | §112 | Final Rejection | 18d overdue | Pending | Apr 06, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial